AFFiRiS biotechnology company has entered into a definitive agreement with AC Immune in regards to the sale of its entire portfolio of anti-alpha-synclein immunotherapies in exchange for shares in AC Immune with regard to all Swiss law aspects. AFFiRiS is an Austrian biotechnology company developing vaccines for the treatment of neurodegenerative and cardiometabolic diseases such as […]
Asml Holding has agreed to sell a 100% stake in BG Medical Applications, SwissOptic and SwissOptic Co., to Jenoptik. BG Medical Applications is a supplier of high-precision, custom optical components for the medical technology sector based
Labster, a platform for virtual labs and interactive science, has signed a definitive agreement to acquire UbiSim, the virtual reality training platform for nursing, based in Lausanne. Labster focuses on early nursing education, offering simulations
CombiGene and Spark Therapeutics, a member of the Roche Group and a fully integrated, commercial gene therapy company dedicated to the fight against genetic diseases, have entered into an exclusive collaboration and licensing agreement for
Gyrus Capital backed DuPont Sustainable Solutions (DSS), a provider of operations management consulting services has acquired Sofies Group, a global sustainability project management and consulting firm with offices in Geneva, Zurich, London and Bangalore. This
Exceet Group, a company of the exceet Group, has entered into an agreement with a fund advised by AFINUM Management to sell its portfolio company GS Swiss PCB. The manufacturer of highly miniaturized printed circuit
Katadyn Group, a Swiss-based specialist in portable water filters and trekking food, has been acquired by a group of entrepreneurs led by Kontivia, a long-term, down-to-earth investment company and
Doetsch Grether, a company specializing in marketing and sales of products in the pharmaceutical, OTC and consumer care sectors, has entered into an agreement with global pharmaceutical company Vifor Pharma for the takeover of two
Helix Acquisition Corp, a Nasdaq-listed special purpose acquisition company and MoonLake Immunotherapeutics, a Swiss based clinical-stage biotechnology company focused on creating next-level therapies for inflammatory skin and joint diseases agreed on a business combination. At
All for One Group, specialists in IT/SAP, strategy and management consulting listed in the Prime Standard of the Frankfurt stock exchange, agreed to acquire all of the shares in the Swiss companies ASC Management